Former athlete Serena Williams shared that she has lost 31 pounds due to a medication. The tennis champion has been opening ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

“If an individual sees a medication labeled as a GLP-1 receptor agonist being sold at a very low price point, they should question how the supplier is able to obtain or produce the medication at ...

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become pop… Recommended for you ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Dennis P. Scanlon, PhD: Another trial, Dr Bloomgarden, is the LEADER trial, which showed a cardiovascular benefit for the GLP-1 (glucagon-like peptide-1) receptor agonist, liraglutide.

Between the two groups, obesity was more common among patients with vs. without GLP-1 receptor agonist use (51.9% vs. 41.6%).